Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2008 Apr 14;6(5):575–583. doi: 10.1016/j.cgh.2008.02.035

Figure 5. Serum 2,5-OAS fold-change and EVR in AA (A) and CA (B) patients.

Figure 5

Serum 2,5-OAS concentrations were measured by RIA as described in Materials and Methods. Data expressed as fold change on each day relative to day 0 as described in figure 2. The EVR was defined as in figure 4 and in Materials and Methods. Results were compared between EVR and NEVR using the Wilcoxon rank-sum.